retatrutide triple agonist glp-1 gip glucagon phase 3 2025 glp 1 lr3 Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside Retatrutide is a triple-agonist drug

Wilson B, Whelan K

Retatrutide works on additional receptors beyond semaglutide, which may lead to stronger appetite regulation and more comprehensive metabolic support

Proposed mechanisms of Tesamorelin: Activates GHRH receptors Increases endogenous GH release Elevates IGF-1 production Promotes lipolysis Reduces visceral adipose tissue Why Tesamorelin is unique: Unlike most weight-loss therapies, Tesamorelin appears particularly effective at reducing visceral fat the deep abdominal fat surrounding internal organs that is strongly associated with insulin resistance, cardiovascular disease, and metabolic syndrome

Ibuprofen, in particular, possesses Nf-kB inhibitory activity that may further help reducing excess inflammation/cytokine release in COVID-19 patients (Smart and Fawkes, 2020)

The ordinary white sugar we eat is rapidly absorbed in the upper part of the small intestine, leaving no chance for it to reach the deeper regions of the gut and interact with these receptors